— Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – — Zetomipzomib demonstrated clinically meaningful renal responses with a favorable tolerability profile in an earlier Phase 2 trial — — Renal and autoimmune diseases…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.